Drug intelligence / Profile preview

VDC-2008

Development stage: Discontinued
Lead developer: Bostwick Laboratories
Modality: Cell Therapies, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

VDC-2008 is an investigational autologous cell therapy developed by Bostwick Laboratories for the treatment of advanced prostate cancer. The therapy consists of a patient's own immature dendritic cells, which are obtained from blood-borne precursors and administered as an immunotherapy to stimulate the patient's immune system against cancer cells. The approach leverages the immunostimulatory properties of dendritic cells to enhance anti-tumor immune responses. Development reached early clinical trial phases but was ultimately discontinued.

Other names: Autologous immature dendritic cells

Beyond the preview

Go deeper on VDC-2008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VDC-2008.

Explore the full profile